GlassScriptPhysician profile
Katisha T Vance
NPI 1467526442
$9,762.65
in general payments reported to CMS, 2019-2025
69 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $2,746 · 2021: $1,362 · 2022: $1,817 · 2023: $1,297 · 2024: $1,057 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,236.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,245.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $957.69 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $620.22 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Daiichi Sankyo INC. | $512.99 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $358.12 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Pharmacyclics LLC, An Abbvie Company | $266.62 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $265.28 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $254.07 | 2021-2023 | Precisetumor |
| Abbvie INC. | $239.70 | 2023-2025 | Venclexta |
| Eisai INC. | $227.53 | 2020-2025 | |
| Octapharma USA, INC. | $226.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $175.23 | 2020-2023 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $156.98 | 2021-2024 | |
| Pfizer INC. | $155.59 | 2020-2025 |
Show all 67 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katisha Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.